Screener
Organon OGN Clarinex — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Singulair | 2 | 38 | 40 | 2 | 72 | 74 |
| Nasonex | — | 65 | 65 | — | 71 | 72 |
| Dulera | 23 | 12 | 35 | 34 | 10 | 43 |
| Clarinex | 1 | 30 | 31 | — | 34 | 34 |
| Other Respiratory (1) | 11 | 1 | 12 | 10 | 3 | 13 |
| Non-Opioid Pain, Bone and Dermatology | ||||||
| Arcoxia | — | 59 | 59 | — | 62 | 62 |
| Fosamax | — | 29 | 29 | 1 | 32 | 33 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's clarinex — revenue?
- Organon (OGN) reported clarinex — revenue of $31M in Q1 2026.
- How has Organon's clarinex — revenue changed year-over-year?
- Organon's clarinex — revenue decreased by 8.8% year-over-year, from $34M to $31M.
- What is the long-term trend for Organon's clarinex — revenue?
- Over 4 years (2021 to 2025), Organon's clarinex — revenue has grown at a 2.6% compound annual growth rate (CAGR), from $111M to $123M.
- What does clarinex — revenue mean?
- This metric represents the total gross sales generated from the Clarinex product line, a key component of the company's established medicines portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical therapy over a defined fiscal period. Monitoring this revenue stream helps investors assess the lifecycle maturity and contribution of legacy assets to the company's overall top-line results.
Ask your AI about Organon's clarinex — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude